Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation

Clinical Genetics

Volumn 83, Issue 4, 2013, Pages 359-364

  Stuckless, S ^a   Green, J ^a   Dawson, L ^a   Barrett, B ^a   Woods, M O ^a   Dicks, E ^a   Parfrey, P S ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Endometrial cancer; Gynecological screening; Lynch syndrome; MSH2 mutation; Ovarian cancer

Indexed keywords

PROTEIN MSH2; MSH2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; COLONOSCOPY; CONTROLLED STUDY; DISEASE CARRIER; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PREGNANCY; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; CASE CONTROL STUDY; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; ENDOMETRIAL NEOPLASMS; FOLLOW UP; GENETIC SCREENING; GENETICS; GENITAL NEOPLASMS, FEMALE; GYNECOLOGICAL EXAMINATION; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROCEDURES; VERY ELDERLY;

ADULT; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; GENITAL NEOPLASMS, FEMALE; GYNECOLOGICAL EXAMINATION; HUMANS; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; OVARIAN NEOPLASMS;

EID: 84874983859     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2012.01929.x     Document Type: Article

References (21)

1. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009: 76 (1): 1-18.
2. Hampel H, Stephens JA, Pukkala E et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005: 129 (2): 415-421.
3. Barrow E, Robinson L, Alduaij W et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009: 75 (2): 141-149.
4. Stuckless S, Parfrey PS, Woods MO et al. The phenotypic expression of three MSH2 mutations in large Newfoundland families with Lynch syndrome. Fam Cancer 2007: 6 (1): 1-12.
5. Hendricks YM, Wagner A, Morreau H et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004: 127 (1): 17-25.
6. Ramsoekh D, Wagner A, van Leerdam ME et al. Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hered Cancer Clin Pract 2009:7(1): 17.
7. Senter L, Clendenning M, Sotamaa K et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008: 135 (12): 419-428.
8. Lindor NM, Petersen GM, Hadley DW et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA 2006: 296 (12): 1507-1517.
9. Schmeler KM, Lu KH. Gynecologic cancers associated with Lynch syndrome/HNPCC. Clin Transl Oncol 2008: 10 (6): 313-317.
10. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009: 16 (1): 14-22.
11. Auranen A, Joutsiniemi T. A systematic review of gynaecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand 2011: 90 (5): 437-444.
12. Manchanda R, Menon U, Michaelson-Cohen R, Beller U, Jacobs I. Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. Curr Opin Obstet Gynecol 2009: 21 (1): 31-38.
13. Evans DG, Gaarenstroom KN, Stirling D et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2009: 46 (9): 593-597.
14. Stuckless S, Green JS, Morgenstern M et al. Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation. Clin Genet 2011. DOI: 10.1111/j.1399-0004.2011.01802.x.
15. Boks DES, Trujillo AP, Voogd AC, Morreau H, Kenter GG, Vasen HFA. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 2002: 102 (2): 198-200.
16. Crijnen TEM, Janssen-Heijnen MLG, Gelderblom H et al. Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer 2005: 4 (4): 301-305.
17. Grindedal EM, Renkonen-Sinisalo L, Vasen H et al. Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. J Med Genet 2010: 47 (2): 99-102.
18. Schmeler KM, Lynch HT, Chen LM et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006: 354 (3): 261-269.
19. Chen L, Yang KY, Little SE et al. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 2007: 110 (1): 18-25.
20. Kwon JS, Sun CC, Peterson SK, Cheung MK, Caughey AB. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 2008: 113 (2): 326-335.
21. Yang KY, Caughey AB, Little SE, Cheung MK, Chen LM. A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) families. Fam Cancer 2011: 10 (3): 535-543.